Capricor shows positive HOPE-3 results with endpoints met, regulatory uncertainty, and a strong cash runway into 2026. Find ...

Pivotal Phase 3 randomized, double-blind, placebo-controlled study (n=106) met the primary endpoint (PUL v2.0) and the key ...

The Company plans to submit its response to the CRL, including the results from the HOPE-3 trial, to address the Agency's previous requests for additional data.

Capricor Therapeutics, Inc. soars 450% on positive HOPE-3 DMD results. Discover market impact, growth potential, and risks.

Capricor jumps after Phase 3 data show Deramiocel improves heart function and slows muscle decline in Duchenne muscular ...

US rare diseases focused biotech Capricor Therapeutics shares closed up 371% at $29.96, having leapt a staggering 500% ...

Six months after receiving a surprise rejection due to what the FDA called “lack of substantial evidence of effectiveness,” ...

Capricor Therapeutics (CAPR) just delivered positive topline data from its pivotal Phase 3 HOPE-3 trial of Deramiocel in Duchenne muscular dystrophy, a key late stage milestone that immediately ...

In 105 boys and young men enrolled in the HOPE-3 trial, patients given deramiocel every three months for a year had 54% ...

Shares of Capricor Therapeutics CAPR have skyrocketed 281.9% this week. The massive stock price surge was observed after the ...

Capricor Therapeutics shares gained after analysts said they believe the company can achieve profitability by 2028. The stock rose 8.4% to $29.14 and hit its 52-week high of $14.87 earlier in the ...

Investor Martin Shkreli's big biotech short position is blowing up after the stock's monumental rally over the past week.